Market Overview:
The global drugs for facial erythema market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of facial erythema, rising awareness about available treatment options, and growing demand for prescription and over-the-counter drugs for the treatment of facial erythema. Based on type, the global drugs for facial erythema market can be segmented into prescription drugs and over-the-counter (OTC) drugs. Prescription drug dominates this market owing to their high efficacy in treating various types of facial erythemata. By application, hospital segment dominates this market due to increasing number of hospital admissions owing to various skin diseases including facial erythremas.
Product Definition:
A drug is a substance that has a physiological effect when ingested or otherwise introduced into the body.
Facial erythema is an inflammation of the skin on your face, characterized by redness and warmth. It can be caused by a number of things, including sunburn, allergies, acne, rosacea, and eczema. Drugs for facial erythema are used to treat the condition and reduce inflammation.
Rx:
Rx is short for prescription. It's a term used in the healthcare industry to define the medication given to a patient by a doctor or pharmacist after evaluating the medical condition of that particular patient. In case of drugs, it refers to the generic version of any drug manufactured by pharmaceutical companies and sold in generic form after being approved by FDA (Food and Drug Administration) as safe and effective for its use.
OTC:
OTC stands for Over-the-Counter and it's used in the drugs for facial erythema market. OTC products are usually sold without a prescription. They do not require any medical prescription to buy or use them, unlike medicines which have specific regulations regarding their sale and distribution. OTC products can be bought from retail stores like Walmart, Amazon, Walgreens etc.
Application Insights:
The other application segment held the largest share of over 70.0% in 2017. Other applications include accidental injury, chronic idiopathic facial erythema and contact dermatitis. Accidental injury is expected to be the fastest-growing segment owing to increasing cases of road accidents across the globe which may lead to facial trauma including burns and cuts on face as well as neck area. As per WHO, in 2016 approximately 1 million people died due to road traffic crashes globally every year with majority of them being pedestrians or cyclists involved in fatal accidents leading to facial trauma that requires treatment at a hospital level for proper management of such injuries thereby driving demand for drugs for accidental injuries from 2018to 2030.
Clinic application is expected register notable growth during forecast period on account of rising awareness regarding early diagnosis.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, advanced healthcare infrastructure and high adoption rate for new drugs are some of the factors contributing to its growth. Moreover, increasing demand for cosmetic products is expected to drive this regional market over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising disposable income and improving healthcare facilities in emerging countries such as China and India. Furthermore, an increase in per capita income has led consumers from middle-income groups seeking medical treatments for aesthetic purposes or chronic diseases such as diabetes or acne vulgaris (acne). These factors are expected to boost product demand over the next eight years.
Growth Factors:
- Increasing prevalence of facial erythema
- Growing awareness about the available treatment options for facial erythema
- Rising demand for effective and safe drugs for the treatment of facial erythema
- Technological advancements in drug delivery systems that can improve the efficacy and safety of drugs for treating facial erythema
- Availability of generic versions of branded drugs that are used to treat facial erythema
Scope Of The Report
Report Attributes
Report Details
Report Title
Drugs for Facial Erythema Market Research Report
By Type
Rx, OTC
By Application
Hospital, Clinic, Other
By Companies
Novartis, Pfizer, Sanofi-Aventis, Merck, Enzon Pharmaceuticals, Bayer, Astellas Pharma, GSK, Abbott, Novartis
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
181
Number of Tables & Figures
127
Customization Available
Yes, the report can be customized as per your need.
Global Drugs for Facial Erythema Market Report Segments:
The global Drugs for Facial Erythema market is segmented on the basis of:
Types
Rx, OTC
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Pfizer
- Sanofi-Aventis
- Merck
- Enzon Pharmaceuticals
- Bayer
- Astellas Pharma
- GSK
- Abbott
- Novartis
Highlights of The Drugs for Facial Erythema Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Rx
- OTC
- By Application:
- Hospital
- Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Drugs for Facial Erythema Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no one answer to this question as the best drugs for facial erythema will vary depending on the person's specific symptoms and medical history. However, some common types of drugs used to treat facial erythema include topical corticosteroids (such as hydrocortisone or prednisolone), anti-inflammatory medications (such as ibuprofen or naproxen), and retinoids (such as tretinoin).
Some of the key players operating in the drugs for facial erythema market are Novartis, Pfizer, Sanofi-Aventis, Merck, Enzon Pharmaceuticals, Bayer, Astellas Pharma, GSK, Abbott, Novartis.
The drugs for facial erythema market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Drugs for Facial Erythema Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Drugs for Facial Erythema Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Drugs for Facial Erythema Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Drugs for Facial Erythema Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Drugs for Facial Erythema Market Size & Forecast, 2020-2028
4.5.1 Drugs for Facial Erythema Market Size and Y-o-Y Growth
4.5.2 Drugs for Facial Erythema Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Rx
5.2.2 OTC
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Drugs for Facial Erythema Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Drugs for Facial Erythema Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Rx
9.6.2 OTC
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Rx
10.6.2 OTC
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Rx
11.6.2 OTC
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Rx
12.6.2 OTC
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Rx
13.6.2 OTC
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Drugs for Facial Erythema Market: Competitive Dashboard
14.2 Global Drugs for Facial Erythema Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Pfizer
14.3.3 Sanofi-Aventis
14.3.4 Merck
14.3.5 Enzon Pharmaceuticals
14.3.6 Bayer
14.3.7 Astellas Pharma
14.3.8 GSK
14.3.9 Abbott
14.3.10 Novartis
